A Nonrandomized Phase 1/2 Clinical Trial

A Nonrandomized Phase 1/2 Clinical Trial - PubMed

The findings of this study suggest that the recommended dose of trabectedin for use in combination with this irradiation regimen is 1.5 mg/m2.

A Phase 1/2 Nonrandomized Clinical Trial - PubMed

To evaluate the safety and efficacy of doxorubicin in combination with pembrolizumab in patients with advanced, anthracycline-naive sarcomas.

A Phase 1/2 Study of INCB001158 in ... - Incyte Clinical Trials

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/ ...

Assessment of Safety and Efficacy of Combined Trabectedin and ...

This nonrandomized phase 1/2 clinical trial evaluates the use of trabectedin in combination with low-dose radiotherapy for treating ...

Treatment Outcomes and Safety of Mobocertinib in Platinum ...

This 3-part, open-label, multicenter, phase 1/2 nonrandomized clinical trial (ClinicalTrials.gov identifier: NCT02716116; trial protocol in ...

Advanced/Metastatic - Incyte Clinical Trials

This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination ...

Randomized and Single-Arm Trials - Friends of Cancer Research

Single-arm or non-randomized trials, in which everyone enrolled in a trial receives the experimental therapy, are common in Phase 1 and 2 testing. While Phase 3 ...

Efficacy of pembrolizumab in patients with advanced cancer of ...

1 2 Despite advances in treatment of metastatic cancers with known ... a nonrandomized phase 2 clinical trial. JAMA Oncol 2020;6:1931.doi:10.1001 ...

An Overview of Phase 2 Clinical Trial Designs

Phase 1/2 trials incorporating toxicity and efficacy endpoints, such ... When can nonrandomized studies support valid inference regarding ...

Clinical Trials Using Futibatinib - NCI

This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study ... trial studies the effect of futibatinib and pembrolizumab in treating patients ...

Clinical activity of durvalumab for patients with advanced mismatch ...

Immune-related adverse events occurred in 14 women, mostly grades 1–2. ... a nonrandomized phase 1 clinical trial. JAMA Oncol 2020;6:1766–72.doi ...

ClinicalTrials.gov: Home

... and nonrandomized. Arm. A group or subgroup of participants ... A phase of research to describe clinical trials that gather more information about a drug's ...

Clinical Trials - National Organization for Rare Disorders

Neurogene, Inc. is sponsoring a phase 1/2 interventional, prospective, non-randomized, first in human (FIH), open-label study of a single dose ...

Clinical Trials Using Tislelizumab - NCI

A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics ... This is an open-label, multicenter, nonrandomized Phase 1 and 2 clinical ...

An Overview of Phase 2 Clinical Trial Designs

Phase 1/2 trials incorporating toxicity and efficacy endpoints, such as the ... When can nonrandomized studies support valid inference regarding effectiveness or ...

Trial Description - Dana-Farber Cancer Institute

Find a Clinical Trial. Print Email. A Non-Randomized, Open-Label, Multi-Center Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Patients with ...

Sarcoma Clinical Trials - SFA

This phase 2 study is a nonrandomized, open label study enrolling patients ... This is a multicenter, open label, Phase 1/2 study of YH001 initially ...

ClinicalTrials.gov Glossary Terms

... and nonrandomized. Arm. A group or subgroup ... A phase of research to describe clinical trials that gather more information about a drug's ...

Registration and Synopses of our Clinical Trials/Clinical Study Reports

Phase 1, Open-label, Non-randomized Study to Evaluate the Pharmacokinetics ... Study title, Clinical Study Reports Synopsis. Recombinant Protein COVID-19 Vaccine ...

Trial Phases 1, 2 & 3 Defined | Clinical Research Management (CRM)

Clinical Trials Phases Defined. Phase I. Phase I trials are concerned primarily with establishing a new drug's safety and dose range in about 20-100 healthy ...